Contents
Special Issue Topic

Theranostic Frontiers in Neuro-Oncology

Guest Editor

Prof. Chunsheng Kang E-Mail

Deputy Director of Tianjin Neurology Institute, Director of Neuro-tumor Laboratory of Tianjin Medical University General Hospital, Tianjin, China

Research Keywords: Nano-medicine; signaling pathways; exosome and endocytosis; gene editing; neuro-oncology

About the Special lssue

Among the tumors of the central nervous system, glioblastoma is currently the most challenging tumor for neurosurgeons. Benign tumors are also challenging diseases for surgical procedures because of deep location with brain. In recent years, with the development of genomics, proteomics and metabolomics, the understanding of neuro-oncology has been deepened, and new diagnostic markers, diagnostic techniques and treatment strategies have been developed in both clinical diagnosis and therapeutics. The special issue will focus on the application of new methods, viewpoints and technologies for the diagnosis and treatment of brain tumors including brain metastases. Novel research methods including immune markers and single-cell sequencing are also welcome. The topic will cover the scope of imaging, pathology, neurosurgery, neuro-oncology and basic research. Reviews, comments and research article within the scope are welcomed for submission.

Keywords: Neuro-oncology; brain metastasis; imaging; surgical technology; pathology; biomarker; single cell sequencing; immunology

Published Articles

Open Access Original Article
Imaging of supratentorial ependymomas with radio-pathological correlation
Aim: Supratentorial ependymoma (STE) is a rare tumor with distinct genetic alterations, whose imaging features have been scarcely studied. This study aims to review the computed tomography (CT) a
Published: June 27, 2024 Explor Target Antitumor Ther. 2024;5:766–779
1400 17 0
Open Access Review
Research progress in molecular pathology markers in medulloblastoma
Medulloblastoma (MB) is the commonest primary malignant brain cancer. The current treatment of MB is usually surgical resection combined with radiotherapy or chemotherapy. Although great
Published: February 28, 2023 Explor Target Antitumor Ther. 2023;4:139–156
2170 32 2
Open Access Review
Liquid biopsy and glioblastoma
Glioblastoma is the most common and malignant primary brain tumor. Despite a century of research efforts, the survival of patients has not significantly improved. Currently, diagnosis is based on ne
Published: February 25, 2023 Explor Target Antitumor Ther. 2023;4:28–41
4280 82 15
Open Access Perspective
Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
Among the malignant tumors in the central nervous system (CNS), glioma is the most challenging tumor to the public society, which accounts for the majority of intracranial malignant tumors with impa
Published: December 27, 2022 Explor Target Antitumor Ther. 2022;3:817–827
4855 1744 7
Open Access Review
Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers
In this era of cancer immunotherapy, the response rates of immune checkpoint blockers (ICBs) are still too low and the adverse events may also be significant. Of the ways of patching up such deficit
Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:676–693
2614 26 1
Open Access Original Article
N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas
Aim: Lower grade gliomas [LGGs; World Health Organization (WHO) grades 2 and 3], owing to the heterogeneity of their clinical behavior, present a therapeutic challenge to
Published: September 30, 2022 Explor Target Antitumor Ther. 2022;3:553–569
2198 41 2